Don Payan, MD
Don Payan, MD, is an experienced hands-on biotechnology physician-scientist-executive. He is founder of biotechnology companies Khepri and Rigel.
Don has organized and led multidiscipline, targeted drug discovery and development teams in the areas of immunology, oncology and muscle wasting diseases. His teams have discovered and developed the first FDA-approved oral SYK inhibitor for an autoimmune disease as well as an additional 12 IND candidates.
Don began his career as a faculty member of medicine at the University of California, San Francisco and the Howard Hughes Medical Institute. He is an author of over 200 published articles and chapters and holds more than 70 issued patents. He is a member of the American Society of Clinical Investigation.
Don received his BS in physics and his MD from Stanford University and his MS in physics from Massachusetts Institute of Technology (MIT). Don completed his residency in Internal Medicine and fellowship in Infectious Diseases at the Massachusetts General Hospital, and a fellowship in Allergy-Immunology at Harvard Medical School.